Compliance and completion rates for the EORTC QLQ-C30 and EuroQoL EQ-5D
| . | QLQ-C30 . | EQ-5D . | ||
|---|---|---|---|---|
| Pembrolizumab n = 146 . | BV n = 150 . | Pembrolizumab n = 146 . | BV n = 150 . | |
| Baseline | ||||
| Completion | 134 (91.8) | 138 (92.0) | 135 (92.5) | 140 (93.3) |
| Compliance | 134/146 (91.8) | 138/150 (92.0) | 135/146 (92.5) | 140/150 (93.3) |
| Week 6 | ||||
| Completion | 139 (95.2) | 138 (92.0) | 139 (95.2) | 138 (92.0) |
| Compliance | 139/146 (95.2) | 138/149 (92.6) | 139/146 (95.2) | 138/149 (92.6) |
| Week 12 | ||||
| Completion | 132 (90.4) | 126 (84.0) | 133 (91.1) | 126 (84.0) |
| Compliance | 132/143 (92.3) | 126/142 (88.7) | 133/143 (93.0) | 126/142 (88.7) |
| Week 18 | ||||
| Completion | 115 (78.8) | 90 (60.0) | 115 (78.8) | 90 (60.0) |
| Compliance | 115/129 (89.1) | 90/111 (81.1) | 115/129 (89.1) | 90/111 (81.1) |
| Week 24 | ||||
| Completion | 103 (70.5) | 68 (45.3) | 103 (70.5) | 69 (46.0) |
| Compliance | 103/120 (85.8) | 68/85 (80.0) | 103/120 (85.8) | 69/85 (81.2) |
| Week 36 | ||||
| Completion | 91 (62.3) | 45 (30.0) | 91 (62.3) | 45 (30.0) |
| Compliance | 91/106 (85.8) | 45/58 (77.6) | 91/106 (85.8) | 45/58 (77.6) |
| Week 48 | ||||
| Completion | 74 (50.7) | 27 (18.0) | 75 (51.4) | 27 (18.0) |
| Compliance | 74/85 (87.1) | 27/35 (77.1) | 75/85 (88.2) | 27/35 (77.1) |
| . | QLQ-C30 . | EQ-5D . | ||
|---|---|---|---|---|
| Pembrolizumab n = 146 . | BV n = 150 . | Pembrolizumab n = 146 . | BV n = 150 . | |
| Baseline | ||||
| Completion | 134 (91.8) | 138 (92.0) | 135 (92.5) | 140 (93.3) |
| Compliance | 134/146 (91.8) | 138/150 (92.0) | 135/146 (92.5) | 140/150 (93.3) |
| Week 6 | ||||
| Completion | 139 (95.2) | 138 (92.0) | 139 (95.2) | 138 (92.0) |
| Compliance | 139/146 (95.2) | 138/149 (92.6) | 139/146 (95.2) | 138/149 (92.6) |
| Week 12 | ||||
| Completion | 132 (90.4) | 126 (84.0) | 133 (91.1) | 126 (84.0) |
| Compliance | 132/143 (92.3) | 126/142 (88.7) | 133/143 (93.0) | 126/142 (88.7) |
| Week 18 | ||||
| Completion | 115 (78.8) | 90 (60.0) | 115 (78.8) | 90 (60.0) |
| Compliance | 115/129 (89.1) | 90/111 (81.1) | 115/129 (89.1) | 90/111 (81.1) |
| Week 24 | ||||
| Completion | 103 (70.5) | 68 (45.3) | 103 (70.5) | 69 (46.0) |
| Compliance | 103/120 (85.8) | 68/85 (80.0) | 103/120 (85.8) | 69/85 (81.2) |
| Week 36 | ||||
| Completion | 91 (62.3) | 45 (30.0) | 91 (62.3) | 45 (30.0) |
| Compliance | 91/106 (85.8) | 45/58 (77.6) | 91/106 (85.8) | 45/58 (77.6) |
| Week 48 | ||||
| Completion | 74 (50.7) | 27 (18.0) | 75 (51.4) | 27 (18.0) |
| Compliance | 74/85 (87.1) | 27/35 (77.1) | 75/85 (88.2) | 27/35 (77.1) |
Data are n (%) unless otherwise specified.